Rising Healthcare Expenditure Fuels Growth In The Gastroparesis Market Emerges as a Core Driver of the Gastroparesis Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gastroparesis Market Through 2025?
The overall scale of the gastroparesis market has demonstrated consistent upward movement across recent periods, projecting an expansion from its 2024 valuation of $6.84 billion to reach $7.15 billion by 2025, reflecting a composite annual growth rate (CAGR) of 4.6 percent, with this preceding expansion largely driven by factors such as the societal shift towards an older demographic, the rising incidence of diabetes mellitus, enhanced comprehension of various digestive ailments, the refinement of prevailing therapeutic regimens, and greater public consciousness regarding gastroparesis conditions.

What's the Projected Size of the Global Gastroparesis Market by 2029?
Anticipating substantial expansion in the coming years, the market for gastroparesis is projectd to reach a valuation of $8.78 billion by 2029, exhibiting a Compound Annual Growth Rate (CAGR) of 5.3%. This forthcoming surge in market size is fundamentally driven by the creation of innovative treatment modalities, the broader implementation of tailored medical strategies, the incorporation of digital healthcare tools, improvements in overall healthcare infrastructure, and a greater emphasis placed on timely disease identification. Key developments shaping this market throughout the forecast duration involve progress in gastric electrical stimulation treatments, escalating investigations into stem cell therapies, greater acceptance of surgical procedures requiring minimal invasion, heightened utilization of portable health monitoring equipment, and a central orientation towards care models designed around the individual patient's needs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Top Growth Drivers in the Gastroparesis Industry: What's Accelerating the Market?
Anticipated increases in spending on healthcare are poised to stimulate the expansion of the gastroparesis market moving ahead, as healthcare expenditure encompasses the aggregate resources designated for health provisions, covering outlays associated with medical facilities, practitioners, nursing care, dentistry, pharmaceuticals, and public health programs; this upward trend in healthcare spending stems from several elements, including a maturing demographic, advancements in medical apparatus, a greater prevalence of long-term ailments, and escalating consumer demands for superior medical attention, ultimately benefiting the gastroparesis sector by augmenting financial backing for discovery and product enhancement, broadening therapeutic choices, and improving patient avenues to expert medical attention, exemplified by the UK's Office for National Statistics reporting a 5.6% surge in health spending between 2022 and 2023, a marked acceleration from the 0.9% rise seen the prior year, with the UK's total healthcare expenditure reaching approximately $317.63 billion (292$ billion) in 2023, thus establishing rising healthcare investment as a key market driver for gastroparesis.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12189&type=smp

What Trends Will Shape the Gastroparesis Market Through 2029 and Beyond?
Leading enterprises participating in the gastroparesis arena are actively creating novel apparatuses with the objective of boosting their financial returns within this sector. Gastroparesis treatment apparatuses encompass medical implements engineered to aid in controlling or easing the manifestations connected with gastroparesis, a disorder marked by sluggish gastric evacuation. As an illustration, in the year 2022, Enterra Medical Inc., a medical technology firm situated in the United States, introduced its Enterra Therapy for addressing gastroparesis. This Enterra Therapy setup utilizes a neurostimulator that is surgically placed to emit mild electrical signals, potentially providing respite from persistent symptoms of sickness and vomiting tied to gastroparesis. This particular treatment is intended for adults between the ages of 18 and their seventieth year who suffer from persistent, difficult-to-treat (medication-unresponsive) nausea and vomiting that stems from gastroparesis of either diabetic or unknown cause.

What Are the Main Segments in the Gastroparesis Market?
The gastroparesismarket covered in this report is segmented -

1) By Treatment Modality: Medications; Dietary Modifications; Medical Devices; Other Therapies
2) By Gastroparesis Type: Idiopathic; Diabetic; Post- Surgical; Other Types
3) By Patient Demographics: Pediatric Gastroparesis; Adult Gastroparesis
4) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Other Distribution Channels
5) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Home Care Settings

Subsegments:
1) By Medications: Prokinetic Agents; Antiemetic Medications; Pain Management Medications
2) By Dietary Modifications: Low-Fiber Diets; Small, Frequent Meals; Pureed Or Liquid Diets
3) By Medical Devices: Gastric Electrical Stimulation Devices; Enteral Feeding Tubes
4) By Other Therapies: Acupuncture; Behavioral Therapies; Nutritional Supplements

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12189&type=smp

Which Top Companies are Driving Growth in the Gastroparesis Market?
Major companies operating in the gastroparesis market include Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Theravance Biopharma Inc., RedHill Biopharma Ltd., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.

Which Regions Will Dominate the Gastroparesis Market Through 2029?
North America was the largest region in the gastroparesis market in 2024. The regions covered in the gastroparesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12189

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.